Aspirin: plasma concentration and effects.

  title={Aspirin: plasma concentration and effects.},
  author={Jake J. Thiessen},
  journal={Thrombosis research. Supplement},
  • J. Thiessen
  • Published 1983
  • Biology, Medicine
  • Thrombosis research. Supplement

Inhibitory effect of acetylsalicylic acid on platelet function in patients with completed stroke or reversible ischemic neurologic deficit.

It is concluded that 75 mg acetylsalicylic acid per day is adequate to inhibit platelet hyperfunction and effectively corrected the abnormal plasma thromboxane B2 concentrations, adenosine diphosphate threshold concentrations, and circulating platelet aggregate ratios.

Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes

Higher doses of aspirin have not been shown to have an adverse interaction with the potent P2Y12 inhibition provided by prasugrel and double-dose clopidogrel, which potentially suggests that the mechanism for this interaction is not related to the inhibition of platelet P2y12 receptors or could simply be a chance finding.

Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid

  • N. Yeomans
  • Medicine
    Expert review of gastroenterology & hepatology
  • 2011
The pharmacology of the component agents and the evidence for efficacy of the combination of esomeprazole and low-dose ASA are reviewed.

Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin

Combining aspirin and PPIs into one tablet is an effective approach to address aspirin-related GI adverse effects and increase adherence to aspirin therapy for the prevention of cardiovascular diseases.

Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients

Patients at risk of ASA-induced gastroduodenal ulcer might benefit from a fixed ASA and proton pump inhibitor (PPI) combination, and attention must be paid on the appropriate use of such combination, still balancing the risk:benefit ratio in a real-life setting.

Effects of Acetylsalicylic Acid on Increase of Fibrin Network Porosity and the Consequent Upregulation of Fibrinolysis

ASA at the concentrations used did not influence the rate of fibrinogen gelation by thrombin, however, assembly offibrin monomers was most probably altered, leading to enhancement of fibin fiber thickness, and a looser network was constructed by the thicker fibr in fibers, which benefits fibrinolysis.

CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.

The data indicate that the effectiveness of chemopreventive drugs can be modulated by the genotype of metabolizing enzymes, and specifically the association between nonaspirin NSAIDs and adenoma risk.

UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin

The variant UGT1A6*2 or polymorphisms in other UGTs that are in linkage disequilibrium with UGT2*2 may confer more rapid glucuronidation of salicylic acid than the wild-type UGT 1A6 *1/*1.

Combined dipyridamole and aspirin pellet formulation for improved oral drug delivery. Part 1: Development pharmaceutics.

Examination of this material by IR spectroscopy, differential scanning calorimetry and X-ray diffraction indicated some free drug, preferentially soluble under gastric pH conditions.

CYP 2 C 9 and UGT 1 A 6 Genotypes Modulate the Protective Effect of Aspirin on Colon Adenoma Risk 1

The data indicate that the effectiveness of chemopreventive drugs can be modulated by the genotype of metabolizing enzymes, particularly in aspirin users who carry CYP2C9 variant alleles.



The effect of salicylates on the hemostatic properties of platelets in man.

These studies lend further support to the hypothesis that ingestion of aspirin, in contrast to sodium salicylate, prolongs the bleeding time by inhibiting the release of platelet ADP, perhaps reflecting the findings in other cell systems which suggest that aspirin alters membrane permeability.

Human platelet response to three salicylate dosage forms.

No correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations.

Pharmacokinetics of Acetylsalicylic Acid and Salicylic Acid After Intravenous Administration in Man

The pharmacokinetics of acetylsalicylic acid (ASA, 650 mg.) and salicylic acid (SA, 500 mg.) were studied following intravenous administration in males. The resultant plasma concentration-time curves

Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition.

The interference with aspirin of its major endogenous metabolite should be borne in mind when interpreting results obtained with high dose aspirin or during repeated administration of this drug.

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of

Salicylate accumulation kinetics in man.

It is thus important to make upward adjustments of dosage cautiously, allowing sufficient time for body levels to reach the new steady state before the dosage is increased still further, according to the time required to attain the plateau.

Influence of food and fluid ingestion on aspirin bioavailability.

Plasma salicylate levels were not influenced markedly by the various treatments, although levels were higher in fasted than in nonfasted subjects during the 1st hr after dosing, and fat pretreatment tended to produce higher levels than other treatments.